Nov 28, 2022 8:30am EST Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022
Nov 09, 2022 8:55pm EST Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Oct 24, 2022 8:30am EDT Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Oct 13, 2022 8:30am EDT Veru to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Sep 21, 2022 8:30am EDT Veru to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th, 2022
Sep 19, 2022 12:15pm EDT Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Sep 07, 2022 1:45pm EDT Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Sep 06, 2022 8:30am EDT Veru to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12th, 2022
Aug 22, 2022 8:30am EDT Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration
